Elephas Biosciences

Elephas Biosciences is pioneering a novel functional diagnostics platform designed to predict immunotherapy response using live tumor tissue. Its core technology, elive™, preserves the native tumor microenvironment and measures dynamic cytokine activity ex vivo to provide a more biologically relevant prediction of therapeutic efficacy than static biomarkers. The company is currently validating its platform through multiple observational clinical trials while engaging with pharmaceutical R&D, research scientists, and medical oncologists through partnership and early access models. Elephas operates as a private, pre-revenue company focused on establishing the clinical utility of its diagnostic approach.

The elive™ platform is a functional diagnostic assay that uses live tumor biopsies preserved in a proprietary hydrogel. It employs an automated cutting instrument for standardization and a sequential treatment strategy to measure dynamic cytokine responses ex vivo, predicting patient response to immunotherapies.

Elephas competes with companies offering static biomarker tests (e.g., PD-L1 IHC, MSI, TMB) and other functional diagnostic approaches, such as organoid or patient-derived xenograft models. Its key differentiation is the preservation of the live tumor microenvironment and the measurement of dynamic cytokine activity, claiming a more biologically relevant prediction of immunotherapy response.